Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
6
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
boston top stories
startups
alzheimer's disease
biogen
cancer
cancer immunotherapy
deals
europe blog main
europe top stories
clinical trials
covid-19
What
bio
roundup
6
×
acquisitions
ceo
drug
biggest
covid
daniel
gilead
ipo
medicines
new
o’day
sciences
abbvie’s
activity
ahead
albert
announced
approval
approvals
biofourmis
biogen
biogen’s
biopharmaceutical
bourla
bucks
build
buy
cancer
celebrate
chance
clamped
collabs
companies
company
company’s
convo
corner
crispr
Language
unset
unknown
Current search:
roundup
×
" gilead sciences "
×
" seattle top stories "
×
novartis
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More